Bortezomib, Melphalan, & Dexamethasone in Treating Patients With Primary

Status Completed

Clinical Trial Summary

RATIONALE: Giving bortezomib together with melphalan and dexamethasone may be an effective treatment for primary amyloidosis and light chain deposition disease. PURPOSE: This phase II trial is studying how well giving bortezomib together with melphalan and dexamethasone works in treating patients with primary amyloidosis or light chain deposition disease.

Clinical Trial Description

OBJECTIVES: Primary - Determine the complete hematologic response rate at 12 months. Secondary - Determine the overall hematologic response rate. - Determine the organ response rate. - Determine time to treatment failure. - Determine the overall survival. OUTLINE: This is a multicenter study. Patients receive oral melphalan on days 1-4, bortezomib IV on days 1, 8, 15, and 22, and dexamethasone orally or IV on days 1, 2, 8, 9, 15, 16, 22, and 23. Treatment repeats every 4-6 weeks for up to 20 courses in the absence of disease progression or unacceptable toxicity. Blood, urine, and bone marrow aspirates are collected at baseline and periodically after treatment to permit the correlation of clinical results with measured molecular events. A single baseline peripheral blood DNA sample is collected for future association studies linking disease onset, progression, and response to administered therapy with single nucleotide polymorphisms. Blood plasma and urine samples are evaluated for proteomic markers associated with disease progression and therapeutic response. Peripheral blood RNA samples are evaluated for transcriptional response to treatment of peripheral blood lymphocytes. Bone marrow aspirates are collected to extract plasma cells by flow cytometry for gene expression profiling. Quality of life is assessed at the beginning of each course. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00520767
Study type	Interventional
Source	Barbara Ann Karmanos Cancer Institute
Contact
Status	Completed
Phase	Phase 2
Start date	September 2007
Completion date	June 6, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01194791` - Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed	Phase 2
Completed	`NCT02207556` - Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial	Phase 2
Completed	`NCT01078454` - Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis	Phase 3
Completed	`NCT00112593` - Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer	N/A
Completed	`NCT00006251` - Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer	Phase 1/Phase 2
Terminated	`NCT01728259` - First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD	Phase 1
Completed	`NCT01072773` - Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis	Phase 2
Active, not recruiting	`NCT03499808` - S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis	Phase 2
Completed	`NCT00536601` - High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors	N/A
Completed	`NCT00224393` - Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis	Phase 2
Completed	`NCT01199562` - Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
Terminated	`NCT00030381` - Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis	Phase 1
Completed	`NCT00014235` - Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies	N/A
Completed	`NCT00890747` - Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy	Phase 1
Completed	`NCT00025415` - Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction	Phase 1
Completed	`NCT01849783` - Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma	Phase 2
Completed	`NCT01053494` - Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms